7000 drugs to delist from NHI reimbursement schedule

Published: 2002-03-12 07:00:00

Updated: 2002-03-12 07:00:00

The drugs of no completing the efficacy equivalent tests until the end of April seem to be ousted from the NHI reimbursement schedule as planned, the MOHW said on March 7.

The MOHW also said that the above plan would never be postponed again but finalized in April for an official announcement...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK